Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Eledon Pharmaceuticals (ELDN) Invested Capital (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Invested Capital readings, the most recent being $19.5 million for Q4 2017.

  • On a quarterly basis, Invested Capital rose 819.91% to $19.5 million in Q4 2017 year-over-year; TTM through Dec 2017 was $19.5 million, a 819.91% increase, with the full-year FY2017 number at $19.5 million, up 819.91% from a year prior.
  • Invested Capital hit $19.5 million in Q4 2017 for Eledon Pharmaceuticals, down from $20.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $103.5 million in Q4 2014 to a low of -$55.3 million in Q4 2013.
  • Median Invested Capital over the past 5 years was $30.3 million (2016), compared with a mean of $40.2 million.
  • Biggest five-year swings in Invested Capital: plummeted 197.12% in 2016 and later surged 819.91% in 2017.
  • Eledon Pharmaceuticals' Invested Capital stood at -$55.3 million in 2013, then surged by 287.27% to $103.5 million in 2014, then crashed by 97.31% to $2.8 million in 2015, then plummeted by 197.12% to -$2.7 million in 2016, then surged by 819.91% to $19.5 million in 2017.
  • The last three reported values for Invested Capital were $19.5 million (Q4 2017), $20.6 million (Q3 2017), and $23.4 million (Q2 2017) per Business Quant data.